4.8 Review

Peptide-based targeting of immunosuppressive cells in cancer

Journal

BIOACTIVE MATERIALS
Volume 5, Issue 1, Pages 92-101

Publisher

KEAI PUBLISHING LTD
DOI: 10.1016/j.bioactmat.2020.01.006

Keywords

Immunosuppression; Tumor microenvironment; Peptide; Nanoparticle

Funding

  1. National Heart, Lung, and Blood Institute (NHLBI) [R00HL124279]
  2. NIH New Innovator Award [DP2DK121328]
  3. L.K. Whittier Foundation
  4. Ming Hsieh Institute for Research on Engineering-Medicine for Cancer
  5. Women in Science and Engineering Gabilan Assistant Professorship
  6. University of Southern California

Ask authors/readers for more resources

Cancer progression is marked by the infiltration of immunosuppressive cells, such as tumor-associated macrophages (TAMs), regulatory T lymphocytes (Tregs), and myeloid-derived suppressor cells (MDSCs). These cells play a key role in abrogating the cytotoxic T lymphocyte-mediated (CTL) immune response, allowing tumor growth to proceed unabated. Furthermore, targeting these immunosuppressive cells through the use of peptides and peptide-based nanomedicine has shown promising results. Here we review the origins and functions of immunosuppressive cells in cancer progression, peptide-based systems used in their targeting, and explore future avenues of research regarding cancer immunotherapy. The success of these studies demonstrates the importance of the tumor immune microenvironment in the propagation of cancer and the potential of peptide-based nanomaterials as immunomodulatory agents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available